# Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

> **NCT01074346** · — · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 60 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon-β-1a

## Key facts

- **NCT ID:** NCT01074346
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2014-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074346, "Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01074346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*